• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries


News provided by

Research and Markets

Apr 17, 2015, 07:28 ET

Share this article

Share this article


DUBLIN, Apr. 16, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/7qs3dw/corporate) has announced the addition of the "Corporate Reputation of Pharma in 2014 - a Perspective of Diabetes Patient Groups - 2nd edition" report to their offering.

600769
600769

This independent study, funded by the author, represents the perspectives from 130 patient groups with an interest in diabetes on the corporate reputation of 14 individual pharma companies (and of the pharma industry as a whole) in 2014. The results from the respondent diabetes patient groups are compared in this report with those from the entire body of 1,150 patient groups covering all therapy areas which responded to author's report: The Corporate Reputation of Pharma in 2014 - the Patient Perspective, published in February 2015, and with the responses of diabetes patient groups in the previous year's survey (2013).

- Findings based on a survey of 130 patient groups with an interest in diabetes from 34 countries
- Survey conducted November 2014 to January 2015

About the corporate stars

- Novo Nordisk holds for 2014 the best corporate reputation out of all 14 pharma companies reviewed in this report, according to the patient groups worldwide with an interest in diabetes. The Denmark-based global healthcare company moves up to the top spot from second in 2013, and holds the lead ranking this year for all six of the report's measurement indicators. Novo Nordisk's position is remarkable given the company has had to face similar challengesproducts approvals, pricing battles, product safety issuesas other companies in the very competitive diabetes sector. This new report examines why such might be the case.

- Bayer moved up to second place overall, from fourth in 2013. The diabetes patient groups have ranked the German global enterprise second for its patient-centricity, the quality of its patient information and its integrity. Although Bayer does not produce diabetes drugs it has a number of treatments for visual impairments brought on by diabetes.

- In 2014 Lilly is in third place overall. The diabetes patient groups rank the US pharma major second for its records on patient safety and transparency.

- Sanofi ranks fourth position overall in 2014. In the latest review, the French biopharma's top ranking by indicator is for its provision of useful, high-quality products, for which the diabetes patient groups place it second.

- Pfizer is in fifth place overall, moving up strongly from 11th in 2013.

What matters to diabetes patient groups:

- Diabetes patient groups believe that the single most important strategy for improving a pharma company's corporate reputation is that it should have a patient-centred strategy. This was cited as top priority by 19.8% of the groups in 2014, and is close to the views of patient organizations across all therapy areas, 19% of which considered this strategy to be the most important. The views of the diabetes patient groups were also close to those representing all therapy areas in the next most-important factors - patient safety and the provision of high-quality, useful products.

- Opinions diverge on the importance of fair pricing policies to attaining a good corporate reputation; 15.8% of patient groups across all therapy areas consider such policies to be important, but the percentage of diabetes patient organizations holding this view is almost half, at 8.7%. Unlike other therapy areas like cancer, pricing has not been so much in the spotlight. However with diabetes drug prices now increasing, pricing could become more important to diabetes patient groups.

- Developments in the field of diabetes have been particularly fast-paced in recent years, and the patient groups' rankings indicate that a company's reputation is particularly enhanced by its provision not only of effective new drugs but also of efficient administration devices such as needles and pens and blood glucose monitors. There is also wide appreciation of efforts such as DAWN2, the largest global study ever taken to understand the unmet needs of people with diabetes, which was initiated in 2011 by a range of partners including Novo Nordisk, the International Diabetes Federation (IDF) and the International Alliance of Patient Organizations (IAPO).

- The diabetes patient groups also rank multinational pharma's reputation fourth-best out of the eight healthcare industries. In marked contrast, the 1,150 patient groups representing all therapy areas which responded to this annual survey place pharma in sixth position in 2014, ranking it higher only than health insurers (for profit and not-for-profit).

- However, the diabetes patient groups now rank generic drugmakers third for reputation out of the eight healthcare industries, one place above multinational pharma and two positions up from the sixth place which the patient organisations awarded generics firms in 2013. This improved performance appears to be due to the perception among patient groups that access to effective medicines is boosted by the availability of cheaper generic drugs.

Five-year view

- 29.1% of the diabetes patient groups now say they (or the people their organisation represents) believe that the pharma industry's reputation has improved in the last five years. This is a significant improvement on 2013 when just 14.1% of the groups had held this view; moreover, this opinion is now shared by 25.1% of all types of patient organisations. However, another 29.1% of diabetes patient groups now also feel that the industry's reputation has worsened over the period, although this is a drop from the 32.8% holding this opinion in 2013 and compares to 35% of patient organisations across all therapy areas which now take this view.

Conduct report

- An increased number of diabetes patient groups believe that the pharmaceutical industry is excellent or good at innovation; 71% held this view in 2014 compared with 68% in 2013, and 67% of patient organisations across all therapy areas currently agree, the latest survey finds.

- In 2014, diabetes patient groups are far more positive about pharma's abilities to ensure patient safety, with 58% saying that pharma is Excellent or Good at this activity (the equivalent figure for 2013 was 49%). The same is true for pharma's provision of high-quality information to patients50% of respondent diabetes patient groups in 2014 say that pharma is Excellent or Good at this activity, against 41% saying as much in 2013; for having a good relationship with the media50% in 2014, against 44% in 2013; and for having a patient-centred strategy34% in 2014, against 24% in 2013.

- Although not as many diabetes patient groups believe pricing is crucial to having a good corporate reputation, fair pricing policies remain a contentious issue as it is with patient groups from all therapy areas). In 2014, just 17% of diabetes patient groups say that pharma is Excellent or Good at this activitya figure only marginally higher than the 14% of patient groups from all therapy areas saying the same.

Companies Mentioned


- AstraZeneca
- Bayer
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Eli Lilly (Lilly)
- GlaxoSmithKline (GSK)
- Janssen
- Merck & Co (US)
- Novartis
- Novo Nordisk
- Pfizer
- Sanofi
- Servier
- Takeda

For more information visit http://www.researchandmarkets.com/research/7qs3dw/corporate

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.